Regulus Therapeutics Inc. (RGLS) is disappointed as the FDA has turned down its request to lift the clinical hold on RG-101, an investigational treatment of chronic hepatitis C virus infection, requesting more data to be submitted.
from RTT - Biotech http://ift.tt/2jLMaQs
via IFTTT
No comments:
Post a Comment